Fexuprazan hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Fexuprazan hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Fexuprazan hydrochloride can convert its Small molecule drug profile and Na/K-ATPase biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Fexuprazan hydrochloride (query alias: Fexuprazan hydrochloride) |
|---|---|
| Modality / target | Small molecule drug; Na/K-ATPase; Na/K-ATPase inhibitors |
| Highest global status | Approved |
| Originator | Daewoong Pharmaceutical Co., Ltd. |
| Active developers | Daewoong Pharmaceutical Co., Ltd., Yangtze River Pharm Group Shanghai Hai Ni Pharm Co. Ltd., Beijing Daewoong Pharmaceutical R&D Center Co., Ltd |
The MCP disease footprint includes Peptic Ulcer, Gastroesophageal Reflux, Helicobacter pylori infection. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07533266 | Phase 4 | Not yet recruiting | 360 | Proportion of subjects who develop peptic ulcer by Week 24 as assessed by investigator |
| NCT07326904 | Phase 3 | Completed | 145 | Proportion of Participants With Symptom Relief at Week 4 (GERD-Q Score <8) |
| NCT07497893 | Not Applicable | Not yet recruiting | 1000 | Clinically relevant upper gastrointestinal bleeding (CR-UGIB) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Comparing the Efficacy and Safety of Fexuprazan and Lansoprazole for the Prevention of Nonsteroidal Anti-inflammatory Drug-Induced Peptic Ulcer
Phase 3; n=not disclosed; evaluation: Positive. Reported fields: Adverse drug reactions = 4.78 % ; Adverse drug reactions = 8.57 %
Daewoong's Fexuclue achieves higher symptom relief over traditional PPI in phase 3 trials
; n=513; evaluation: 非劣. Reported fields: 全身症状 = 11.9 % ; 全身症状 = 20.4 %
EFFICACY AND SAFETY OF FEXUPRAZAN IN PATIENTS WITH EROSIVEESOPHAGITIS AND MODERATE SEVERITY OF MAJOR SYMPTOMS: POOLED ANALYSIS OF TWO RANDOMIZED CONTROL TRIALS IN SOUTH KOREA AND CHINA
Not Applicable; n=not disclosed; evaluation: not stated. Reported fields: Healing rates of EE = 84.0 % ( -2.80 to 9.23); Healing rates of EE = 86.9 % ( -2.80 to 9.23)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Fexuprazan hydrochloride addresses Peptic Ulcer, Gastroesophageal Reflux, Helicobacter pylori infection. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-04-07 | Sun Pharma to commercialize Daewoong's Fexuclue against GERD and erosive esophagitis in India | Approved | Financial terms not disclosed |
| 2024-04-01 | Daewoong, Chong Kun Dang to co-market GERD drug Fexuclue | Approved | Financial terms not disclosed |
| 2023-07-27 | Daewoong Pharmaceutical’s Fexuprazan takes its first step into Africa… Entering into a partnership with Cooper Pharma, the No. 1 pharmaceutical company in Morocco in the field of digestive health | NDA/BLA | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
